Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Late-Stage Trials

Ingelheim, Tuesday, 28 April 2026.
Boehringer Ingelheim’s new obesity drug, survodutide, delivered an impressive 16.6% (17.8 kg) weight reduction in Phase III trials, signaling fierce new competition for current market leaders.